tiprankstipranks
TC Biopharm (Holdings) Plc Sponsored ADR (TCBP)
NASDAQ:TCBP

TC Biopharm (Holdings) Plc Sponsored ADR (TCBP) Income Statement

95 Followers

TC Biopharm (Holdings) Plc Sponsored ADR Income Statement

Last quarter (Q ), TC Biopharm (Holdings) Plc Sponsored ADR's total revenue was £―, a decrease of -100.00% from the same quarter last year. In Q, TC Biopharm (Holdings) Plc Sponsored ADR's net income was £―. See TC Biopharm (Holdings) Plc Sponsored ADR’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20
Total Revenue
£ 989.33K£ 3.84M£ 1.98M£ 1.98M
Cost of Revenue
----
Gross Profit
-£ 3.84M£ 1.98M-
Operating Expense
£ 5.47M£ 22.76M£ 12.70M£ 8.32M
Operating Income
£ -4.48M£ -18.92M£ -10.72M£ -6.34M
Net Non Operating Interest Income Expense
£ -3.08M£ 2.21K£ 33.00£ -291.03K
Other Income Expense
£ -271.35K£ -15.92M£ 4.18M-
Pretax Income
£ -11.82M£ -3.11M£ -14.98M£ -6.63M
Tax Provision
£ -895.03K£ -1.72M£ -1.41M£ -1.17M
Earnings From Equity Interest Net Of Tax
----
Net Income Common Stockholders
£ -10.93M£ -1.39M£ -13.58M£ -5.46M
Basic EPS
-£ -2.02--
Diluted EPS
-£ -2.02--
Basic Average Shares
-£ 687.97K--
Diluted Average Shares
-£ 687.97K--
Dividend Per Share
----
Total Operating Income As Reported
----
Reported Normalized Basic E P S
----
Reported Normalized Diluted E P S
----
Rent Expense Supplemental
----
Total Expenses
£ 5.47M£ 22.76M£ 12.70M£ 8.32M
Net Income From Continuing And Discontinued Operation
£ -10.93M£ -1.39M£ -13.58M£ -5.46M
Normalized Income
£ -10.69M--£ -5.46M
Interest Expense
£ 3.08M--£ 292.06K
EBIT
£ -8.75M£ -3.11M£ -14.98M£ -6.34M
EBITDA
£ -8.25M£ -2.40M£ -14.98M£ -5.26M
Currency in GBP

TC Biopharm (Holdings) Plc Sponsored ADR Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis